Cargando…
Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. W...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627986/ https://www.ncbi.nlm.nih.gov/pubmed/34877371 http://dx.doi.org/10.1016/j.dib.2021.107578 |
_version_ | 1784606927368486912 |
---|---|
author | Krasowski, Matthew D. Dolezal, Anna Steussy, Bryan W. Gailey, Michael P. Darbro, Benjamin W. |
author_facet | Krasowski, Matthew D. Dolezal, Anna Steussy, Bryan W. Gailey, Michael P. Darbro, Benjamin W. |
author_sort | Krasowski, Matthew D. |
collection | PubMed |
description | Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. While autoantibody testing may reveal or confirm actionable clinical diagnoses, inappropriate utilization of testing may be low yield and further lead to false positives that may confuse the clinical picture. There is thus opportunity to improve patient care by analyzing patterns of paraneoplastic autoantibody test utilization. The data in this article provides results from detailed retrospective review of patients tested by 7 autoantibody tests or test panels offered by two large reference laboratories in the United States. The data include 1,446 tests performed on 1,338 unique patients at an academic medical center. For all results, detailed chart review revealed main category of presenting symptoms, patient location at time of testing (either inpatient or outpatient), sex, age, whether cancer was present at the time of testing or later detected, and the specific results of the testing. The data are summarized by category of testing and specific autoantibodies. |
format | Online Article Text |
id | pubmed-8627986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86279862021-12-06 Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center Krasowski, Matthew D. Dolezal, Anna Steussy, Bryan W. Gailey, Michael P. Darbro, Benjamin W. Data Brief Data Article Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. While autoantibody testing may reveal or confirm actionable clinical diagnoses, inappropriate utilization of testing may be low yield and further lead to false positives that may confuse the clinical picture. There is thus opportunity to improve patient care by analyzing patterns of paraneoplastic autoantibody test utilization. The data in this article provides results from detailed retrospective review of patients tested by 7 autoantibody tests or test panels offered by two large reference laboratories in the United States. The data include 1,446 tests performed on 1,338 unique patients at an academic medical center. For all results, detailed chart review revealed main category of presenting symptoms, patient location at time of testing (either inpatient or outpatient), sex, age, whether cancer was present at the time of testing or later detected, and the specific results of the testing. The data are summarized by category of testing and specific autoantibodies. Elsevier 2021-11-18 /pmc/articles/PMC8627986/ /pubmed/34877371 http://dx.doi.org/10.1016/j.dib.2021.107578 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Data Article Krasowski, Matthew D. Dolezal, Anna Steussy, Bryan W. Gailey, Michael P. Darbro, Benjamin W. Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title | Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title_full | Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title_fullStr | Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title_full_unstemmed | Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title_short | Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
title_sort | data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center |
topic | Data Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627986/ https://www.ncbi.nlm.nih.gov/pubmed/34877371 http://dx.doi.org/10.1016/j.dib.2021.107578 |
work_keys_str_mv | AT krasowskimatthewd dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter AT dolezalanna dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter AT steussybryanw dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter AT gaileymichaelp dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter AT darbrobenjaminw dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter |